New compositions based on IGF-binding protein sequences are provided. New tools
for high-throughput research are provided. New methods for the treatment of human
disease are provided. IGFBP-3-derived peptide or small molecule is administered
to subjects having disease, thereby alleviating the symptoms of the disease.